SREBF1 and fatty liver disease: In our study, TO-treated db/db mice exhibited more extensive hepatic steatosis than the control group, most likely due to SREBP-1c-mediated up-regulation of lipogenetic genes, such as SCD-1 and FAS, etc [32].